Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2017

View Archived Issues

Restoration of PI3K/Akt/GSK-3beta/ROS signaling pathway for arrhythmias after infarction

Human amniotic mesenchymal stem cell transplantation counteracts bone fragility

VZHE-039 demonstrates to be a promising novel potent antisickling agent

Ascentage Pharma obtains financing to advance apoptosis-targeted novel therapeutics

Protalix Biotherapeutics reports promising interim phase II results on alidornase alfa for CF

Dermira doses first patient in phase III acne study

Global Blood Therapeutics develops KLKB1 inhibitors

ContraVir Pharmaceuticals awarded grant to advance hepatitis B treatment

Vascular Strategies patents mTOR inhibitors

Bayer Pharma describes anticancer agents

Adamas completes phase I trial of ADS-4101

Ardelyx initiates two new trials of RDX-7675 for hyperkalemia

Caelum Biosciences formed to develop CAEL-101

FDA accepts Kura Oncology's IND for ERK inhibitor

FDA grants fast track designation to Neurelis' intranasal diazepam

Positive data reported from phase II study of IONIS-GCGRRx

Preclinical studies demonstrate that Compugen's CGEN-15001 restores immune tolerance

Enterome begins phase I trial of EB-8018 for the treatment of Crohn's disease

Phase IIa study of SER-150 in diabetic nephropathy reaches primary endpoint

Heron reports promising results from phase II postoperative pain program of HTX-011

EndoLogic acquires rights to Alizyme's renzapride

Topline results from confirmatory phase III trial of Macrilen

FDA fast track designation for Enanta's candidate for NASH with liver fibrosis

EMA accepts for review MAA for KRN-23 in X-linked hypophosphatemia

FORUM Pharmaceuticals discloses compounds dor Alzheimer's disease

FDA lifts full clinical hold on pacritinib trials

FDA accepts for review Ironwood's NDA for Duzallo

Ocular Therapeutix reports positive secondary endpoint results from Dextenza phase II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...